The latest announcement is out from Atara Biotherapeutics (ATRA).
Atara Biotherapeutics, Inc. has announced the appointment of Mr. Gregory A. Ciongoli to its Board of Directors, coinciding with a new registered direct offering aimed at raising approximately $36 million in gross proceeds. This capital raise involves the sale of shares and pre-funded warrants exercisable immediately with no expiration. The funds are earmarked for working capital and general corporate purposes, with Mr. Ciongoli’s firm participating in the purchase. The offering, expected to close by September 5, 2024, is subject to standard closing conditions, including Ciongoli’s board appointment.
For an in-depth examination of ATRA stock, go to TipRanks’ Stock Analysis page.
